NCT00129038已完成4 期
A Randomised, Crossover Study Comparing the Biochemical and Platelet Effects of Modified-release Dipyridamole/Aspirin (200mg/25 mg bd; Asasantin Retard®) With Aspirin (75 mg qd) in Coronary Artery Disease Patients With Aspirin Resistance Manifesting as Persistent Thromboxane Formation.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 11
- 试验地点
- 4
- 主要终点
- platelet aggregation in response to arachidonic acid
研究概览
简要总结
The primary objective of this study is to assess whether adding modified-release dipyridamole to aspirin (Asasantin Retard) has measurable effects on markers of platelet function (for example, platelet aggregation) in patients with cardiovascular disease who are known to be resistant to aspirin alone
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Cardiovascular disease (including history of stroke or transient ischaemic attack)
- •Documented evidence of resistance to aspirin
- •Capable of comprehending and communicating effectively with the investigator and staff and of providing informed consent.
- •Willing to give informed consent prior to participation in the trial.
排除标准
- •Any clinically significant condition other than cardiovascular disease.
- •Clinically significant abnormal baseline haematology, blood chemistry or urinalysis findings.
- •Use of dipyridamole, clopidogrel, ticlopidine or any non-steroidal anti-inflammatory agent (NSAID)(including COX-2 inhibitors) during the two weeks before randomisation and during the trial.
- •Active peptic ulceration or history of peptic ulcer disease.
- •Known history of or suspected hypersensitivity to dipyridamole, aspirin, any NSAID or any other component of the test drugs.
- •History of any bleeding disorder.
- •History of cerebral haemorrhage.
- •Resting seated blood pressure less than 90/60mmHg.
- •Participation in any drug clinical trial within sixteen weeks prior to the start of the trial.
- •Any indication of current or previous abuse of alcohol, solvents or drugs.
- •Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (e.g. oral contraceptives, intrauterine devices or surgically sterile).
- •Previous participation in the randomisation phase of this clinical trial.
结局指标
主要结局
platelet aggregation in response to arachidonic acid
时间窗: baseline, day 14, day 30 of each period
次要结局
- flow cytometry measurements from bleeding time samples(day 30 of each period])
- coagulation markers F1.2 and fibrinopeptide A (in bleeding time samples)(day 30 of each period)
- pulse rate and blood pressure(baseline, day 14, day 30 of each period)
- platelet aggregation in response to epinephrine, adenosine diphosphate (ADP) and collagen(baseline, day 14, day 30 of each period)
- serum thromboxane B2(baseline, day 14, day 30 of each period)
- urinary 11-dehydro-thromboxane B2(baseline, day 30 of each period)
- flow cytometry measurements of platelet receptors in blood samples(baseline, day 14, day 30 of each period)
- 6-keto-prostaglandin F1α (in bleeding time samples)(day 30 of each period)
- thromboxane B2 (in bleeding time samples)(day 30 of each period)
- urinary 2,3,-dinor-6-keto-prostaglandin F1α(baseline, day 30 of each period)
- plasma CD40L(baseline, day 14, day 30 of each period)
- bleeding time(day 30 of each period)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
Effects of Acetylsalicylic Acid Compared With the Combination of Acetylsalicylic Acid + Modified-release Dipyridamole on Serum Thromboxane B2 Formation and Platelet Aggregation in Healthy VolunteersHealthyNCT02268773Boehringer Ingelheim27
Unknown
2 期
Phase II Study for the Diagnosis and Functional Assessment of CAD Using Transthoracic-EchodopplerIschemic Heart DiseaseNCT01593644Adenobio N.V75
已完成
4 期
PRoFESS - Prevention Regimen For Effectively Avoiding Second StrokesStrokeNCT00153062Boehringer Ingelheim20,332
终止
4 期
Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced AsthmaExercise Induced AsthmaNCT01070888Boston Children's Hospital6
已完成
1 期
Study to Evaluate Daptomycin Given During Dialysis and After DialysisEnd-stage Renal DiseaseRenal Failure Chronic Requiring HemodialysisNCT00882557Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)16